fda compounding peptides bpc-157 warning panel narrowly backs unapproved peptide drugs – NBC4 Washington New US FDA AdComm Members

The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks

This keeps injection volumes manageable and well within the range of a standard 1 mL insulin syringe

Some of the most common symptoms of Crohns disease include diarrhea and abdominal pains

BPC-157, a stable 15-amino acid pentadecapeptide derived from gastric protective factors, activates the FAK-paxillin and VEGFR2-Akt-eNOS signaling cascades that drive cellular migration, angiogenesis, and wound closure with exceptional stability under diverse physiological conditions